(Q83341354)
Statements
A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis (English)
Vibeke Strand
Stanley B Cohen
Mark C Genovese
David Wofsy
Michael E Weinblatt
Gary S Firestein
Ernest Brahn
Daniel G Baker